The worst Ebola virus disease outbreak in history ended in 2016 after infecting 28,600 people and killing about 11,300 worldwide.
The outbreak led to urgent action by medical experts across the world to combat this devastating disease; including the setting up of trials of vaccines to stop the disease taking hold.
This global commitment to develop a vaccine against the disease suggested eight options, out of a starting pool of 15 candidates, should be evaluated in clinical trials worldwide by the end of 2015.
Professor Sanjeev Krishna, of St George’s University of London’s Institute for Infection and Immunity, said: “An unprecedented Ebola outbreak showed how it is possible for academics, non-governmental organisations, industry and funders to work effectively together very quickly in times of medical crisis. The results of the trial show how a vaccine could best be used to tackle this terrible disease effectively.
“We need a system of specialists, medical experts and organisers that maintains vigilance against outbreak diseases like Ebola.
“We should continue to improve ways to make, evaluate and deliver vaccines when they are needed, often in parts of the world lacking in infrastructure for diagnosing infections and providing treatments.”
He explained that considering the persistent replication of the vaccine which is called rVSV-?GP-ZEBOV in children and adolescents, further studies investigating lower doses in this population are warranted.
The vaccine contains a non-infectious portion of a gene from the Zaire Ebola virus. The St George’s researchers worked with colleagues on a vaccine trial in Gabon.
In addition, lower vaccine doses should be considered when boosting individuals with pre-existing antibodies to Ebolavirus glycoprotein, a finding that has emerged after the vaccine was tested in a country that has experienced Ebolavirus outbreaks in the past.
The vaccine was one of two being examined as a ‘candidate’ option by the World Health Organisation to identify urgently a vaccine to combat the Ebola virus outbreak in West Africa.
The clinical trial was led by colleagues at University of Tübingen in Germany, coordinated by Professor Peter Kremsner with their partner institute CERMEL in Lambaréné, Gabon.
Learn more: Ebola vaccine tested in adults and children in Africa hailed a success
The Latest on: Ebola vaccine
[google_news title=”” keyword=”Ebola vaccine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- Ebola's exponential growthon May 16, 2024 at 5:00 pm
Until and unless a vaccine becomes available in very large quantities, the only way to stop the exponential spread of Ebola in the affected countries is to isolate the victims, a task that is very ...
- Key Considerations: Effective Vaccine Rollout and Uptake in Sierra Leoneon May 15, 2024 at 3:07 am
Sierra Leone received its first shipment of 550,000 malaria vaccines in December 2023, marking a milestone for public health in a country that sees over two million hospital visits for malaria ...
- DNA Medicine Focused INOVIO Pharma Efficiencies Implemented By Leadership Will Help De-Risk Its Platform Technology: Analyston May 14, 2024 at 1:37 pm
Stephens covers INOVIO Pharmaceuticals highlighting its diverse clinical pipeline and FDA's consideration of INO-3107 Phase 1/2 trials for Accelerated Approval. Potential as the first non-surgical RRP ...
- Lassa fever case in Paris: What you need to knowon May 13, 2024 at 11:00 am
A case of Lassa fever has been reported in Paris, France, sparking lurid warnings about the "horrific Ebola-like bug".
- Urgent considerations for booster vaccination strategies against Ebola virus diseaseon May 8, 2024 at 4:30 pm
With two endorsed and prophylactic vaccines against Zaire ebolavirus (referred to hereafter as EBOV), the number of individuals vaccinated against EBOV worldwide is estimated to range between 500 000 ...
- Newsday - Fears over the use of a new Ebola vaccine in DRCongo - BBC Soundson May 8, 2024 at 1:41 am
An MP explains why there's scepticism about the goal of vaccinations ...
- Conference Report - I. Investigating New Vaccines: Ebola and HIVon May 7, 2024 at 5:00 pm
Here, we will review the latest advances in epidemiology and vaccine design for Ebola and HIV infections, discussed at the Vaccine Meeting recently held in Barcelona, Spain. An overview of the ...
- Ebola vaccine verdict up to victimson May 7, 2024 at 5:00 pm
Convention is to keep vaccines from dying people on the ground ... who lie at the threshold of death from Ebola, not deserve the chance to choose if they are willing to try an unproven medication ...
- Creating the next wave of antibody therapies requires innovative collaborationon April 30, 2024 at 9:01 am
Aligning economic incentives with global health goals is not only a moral imperative but a practical necessity for economic security.
- Conference Report - I. Investigating New Vaccines: Ebola and HIVon April 26, 2024 at 5:00 pm
In our efforts to protect ourselves from diseases caused by viruses, we are constantly faced by the challenges posed by a nature that is steadily changing and adapting. These challenges can take ...
via Google News and Bing News